SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AeroVironment, Inc. is a defense technology company delivering integrated capabilities across air, land, sea, space, and cyber. The company develops and deploys autonomous systems, loitering munitions, counter-UAS technologies, space-based platforms, directed energy systems, and cyber and electronic warfare capabilities-built to meet the mission needs of today’s warfighter and tomorrow’s conflicts. At the core of these technologies lies AV_Halo, a modular, mission-ready suite of AI-powered software tools that empowers warfighters and enables full-battlefield dominance: detect, decide, deliver. With a national manufacturing footprint and a deep innovation pipeline, AV delivers proven systems and future-defining capabilities at speed, scale, and operational relevance. The company was founded by Paul B. MacCready, Jr. in July 1971 and is headquartered in Arlington, VA.

AeroVironment Inc.

AeroVironments fiscal Q1 results beat expectations and its funded backlog reached a record, prompting renewed optimism about drone and counter-drone demand. Traders are divided because management maintained its full-year outlook, leaving concerns about growth, profitability and converting orders into revenue alongside the bullish reaction to the backlog.

Ouster, Inc. engages in the provision of high resolution digital lidar sensors that offer advanced 3D vision to machinery, vehicles, robots, and fixed infrastructure assets. The company was founded by Angus Pacala and Mark Frichtl on June 30, 2015 and is headquartered in San Francisco, CA.

Ouster Inc - Ordinary Shares - Class A

Ousters Rev8 lidar partnership with Seneca for autonomous wildfire-response drones is drawing attention as another potential commercial use for its sensing technology. Traders are optimistic about broader adoption across robotics and autonomy, but debate the stocks sharp swings and whether deployments can translate into sustained growth.

Zscaler, Inc. engages in the provision of a cloud-based internet security platform. It offers Zero Trust Exchange, Zscaler Client Connector, Zscaler Internet Access, Zscaler Private Access, Zscaler B2B, Zscaler Cloud Protection, and Zscaler Digital Experience. The company was founded by Jagtar Singh Chaudhry and K. Kailash in September 2007 and is headquartered in San Jose, CA.

Zscaler Inc

Zscalers Investor Day is driving attention, with management reaffirming its outlook, outlining a long-term ARR ambition, and announcing an IBM/Red Hat security collaboration as analysts raised price targets. Traders welcomed the updates and AI-security opportunity, though some remain skeptical that the growth ambitions justify the valuation.

Affirm Holdings, Inc. operates a platform for digital and mobile-first commerce. Its platform consists of three core elements: a point-of-sale payment solution for consumers, merchant commerce solutions, and a consumer-focused app. The company was founded by Max R. Levchin in 2012 and is headquartered in San Francisco, CA.

Affirm Holdings Inc - Ordinary Shares - Class A

Affirm Holdings Inc

Affirms strong quarterly results and upbeat outlook, followed by a wave of analyst upgrades, are driving attention. Traders are split between buyers expecting the growth story to support a recovery and sellers pointing to the sharp post-earnings pullback, profit-taking, and interest-rate concerns.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Teslas recent rally has traders focused on increased Texas Cybercab registrations and stronger September Shanghai sales, while some are also positioning around an anticipated Roadster event. Bulls see momentum and expanding autonomy potential; bears argue the valuation is stretched and the move may fade.

ProShares Trust - ProShares UltraPro Short QQQ -3x Shares

ProShares UltraPro Short QQQ

Traders are using SQQQ to hedge or bet on a Nasdaq pullback, citing concerns about stretched tech and AI valuations, market breadth, and macro risks such as yields and geopolitical tensions. Others point to the Nasdaqs strength and warn that SQQQs leveraged, daily-reset structure can erode value, making it a risky longer-term hold.

Amplify Commodity Trust - Breakwave Tanker Shipping ETF

Breakwave Tanker Shipping ETF

Disruption and security risks around the Strait of Hormuz are keeping tanker freight rates elevated, a key driver for BWETs freight-futures exposure. Traders remain divided between those expecting continued strength while shipping routes are impaired and those warning that peace or normalized traffic could trigger a sharp reversal after the funds steep run-up.

MongoDB, Inc. engages in the development and provision of a general-purpose database platform. The firm's products include MongoDB Enterprise Advanced, MongoDB Atlas, and Community Server. It also offers professional services including consulting and training. The company was founded by Eliot Horowitz, Dwight A. Merriman, Kevin P. Ryan, and Geir Magnusson Jr. in 2007 and is headquartered in New York, NY.

MongoDB Inc - Ordinary Shares - Class A

MongoDB Inc

MongoDB shares are rebounding after a sharp selloff triggered by CEO CJ Desais abrupt departure to Meta, with traders describing the reaction as excessive and pointing to the former CEOs return as interim leader. Bulls also cite upbeat investor-day commentary, AI product launches and an expanded buyback, while skeptics remain concerned about leadership uncertainty and valuation.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candels additional immune-biomarker findings for its prostate cancer candidate CAN-2409, alongside the companys stated plan to submit a BLA in Q4 2026, are driving discussion. Supporters see the data as strengthening the case for the therapy and its broader platform, while skeptics question the limited detail and timing and cite financing, insider-sale, and weak-share-price concerns.

Chainlink is the industry-standard decentralized oracle network that solves the "oracle problem" by connecting smart contracts with real-world data. Blockchains cannot access external information on their own, so Chainlink acts as a secure bridge, enabling smart contracts to react to real-world events using verified, tamper-proof data. It is widely considered one of the first decentralized oracle networks and is the market leader in bringing off-chain data on-chain.  The platform operates through a decentralized network of nodes that fetch, validate, and deliver data to smart contracts. When a contract requests information like a stock price, a committee of independent nodes retrieves and aggregates the data to reach consensus, then delivers a single trustworthy answer. Chainlink offers a suite of services including Data Feeds for asset prices, CCIP for cross-chain token transfers and messaging, Automation for triggering smart contract functions, and Proof of Reserve for verifying asset collateralization.  Chainlink has established itself as critical infrastructure for both DeFi and institutional adoption, with partnerships including Swift, Euroclear, Mastercard, UBS, ANZ, Fidelity International, and J.P. Morgan. Its institutional products include the Chainlink Runtime Environment for tokenized asset workflows, Confidential Compute for privacy-preserving computation, and the Automated Compliance Engine for embedding regulatory rules into smart contracts.  The LINK token is the native asset used to pay node operators for services, fund subscription accounts, and incentivize network security through staking. Node operators stake LINK as collateral, which can be slashed if they provide inaccurate data. Chainlink was co-founded in 2017 by Sergey Nazarov and Steve Ellis, who co-authored the white paper with Ari Juels, and raised $32 million in its September 2017 ICO.

ChainLink

LINKs volatile rebound and breakout attempts have fueled bullish momentum chatter, with traders pointing to Chainlinks institutional and tokenization integrations as support for its long-term infrastructure thesis. Others remain skeptical, citing weak or inconsistent price action and questioning whether network adoption will translate into value for the LINK token.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MetaVia Announces Preclinical Findings Supporting Biological Rationale for DA-1726's Waist Circumference Reduction

MetaVia Announces Preclinical Findings Supporting Biological Rationale for DA-1726's Waist Circumference Reduction MetaVia Announces Preclinical Findings Supporting Biological Rationale for DA-1726's Waist Circumference Reduction PR Newswire CAMBRIDGE, Mass., Sept. 9, 2026 Tissue Distribution Study...

MetaVia Reports Second Quarter 2026 Financial Results and Provides Corporate Update

MetaVia Reports Second Quarter 2026 Financial Results and Provides Corporate Update MetaVia Reports Second Quarter 2026 Financial Results and Provides Corporate Update PR Newswire CAMBRIDGE, Mass., Aug. 6, 2026 All Active Patients Successfully Reached Highest Planned Dose Levels of 48 mg and 64 mg...

MetaVia Announces Completion of Dose Titration in Phase 1 Part 3 Study of DA-1726 for the Treatment of Obesity

MetaVia Announces Completion of Dose Titration in Phase 1 Part 3 Study of DA-1726 for the Treatment of Obesity MetaVia Announces Completion of Dose Titration in Phase 1 Part 3 Study of DA-1726 for the Treatment of Obesity PR Newswire CAMBRIDGE, Mass., July 9, 2026 All Active Patients in Both...

MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum

MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum PR Newswire CAMBRIDGE, Mass., June 17, 2026 CAMBRIDGE, Mass., June 17, 2026...

MetaVia Presents New Late-Breaking Obesity and Metabolic Data at the ADA 2026 Scientific Sessions Supporting DA-1726 Differentiation and Vanoglipel Combination Potential

MetaVia Presents New Late-Breaking Obesity and Metabolic Data at the ADA 2026 Scientific Sessions Supporting DA-1726 Differentiation and Vanoglipel Combination Potential MetaVia Presents New Late-Breaking Obesity and Metabolic Data at the ADA 2026 Scientific Sessions Supporting DA-1726...

Biotech Stocks Are Loading Up on Major 2026 Catalysts and Wall Street Is Watching

Investors continue to focus on companies capable of generating meaningful clinical milestones, regulatory achievements, and commercial opportunities in large underserved markets. Several small-cap healthcare names now have potentially market-moving events scheduled throughout the remainder of 2026, positioning them among closely watched stocks in the biotech and healthcare sectors. $BCDA, $NTHI, $MTVA, $BGMS, $CMND

MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference

MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference PR Newswire CAMBRIDGE, Mass., June 4, 2026 CAMBRIDGE, Mass., June 4, 2026 /PRNewswire/ --MetaVia Inc...

MetaVia Presents Higher-Dose Phase 1 Results for DA-1726 at EASL Congress 2026, Supporting Potential in Obesity and MASH

MetaVia Presents Higher-Dose Phase 1 Results for DA-1726 at EASL Congress 2026, Supporting Potential in Obesity and MASH MetaVia Presents Higher-Dose Phase 1 Results for DA-1726 at EASL Congress 2026, Supporting Potential in Obesity and MASH PR Newswire CAMBRIDGE, Mass., May 27, 2026 48 mg Cohort...

Why MetaVia Stock Is Surging On Friday?

Discover why MetaVia Inc. (NASDAQ: MTVA) stock is surging on Friday following new peer-reviewed data on its MASH treatment, reversing Thursday's dip.read more...

This Emerging Biotech Wave Could Create the Next Monster Healthcare Winners

The biotechnology sector continues attracting speculative capital as investors aggressively position around next-generation oncology, metabolic disease, and CNS therapy platforms. Artificial intelligence, precision medicine, RNA biology, and novel drug delivery technologies are rapidly reshaping how Wall Street evaluates emerging healthcare companies. As larger pharmaceutical companies race to secure pipeline assets and differentiated platforms, smaller clinical-stage companies with compelling preclinical or clinical data are increasingly finding themselves under the spotlight. $AKTX, $NTHI, $MTVA, $HCWB, $BAC, $STT, $BCS

MetaVia, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing multi-modal disease-modifying therapies. Its pipeline includes ANA001, a proprietary oral niclosamide formulation, Gemcabene, which is assessed as an acute indication for COVID-19, NB-01, a treatment for painful diabetic neuropathy, and NB-02, which has the potential to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases. The company was founded on October 30, 2014 and is headquartered in Cambridge, MA.

MetaVia Inc.

IMG, MTVA, USREF, TGL: These Four Stocks Trade Ex-Reverse Split On Friday

Equity

Bullish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Stocktwits

Stocktwits Polls

$MTVA people calling this bullish... 
 
Latest PR : it's a RAT study (again). Tissue distribution in rodents. not humans. Explains stuff we already knew. Stock still dropped 10% on it, market's not buying the hype anymore. Also quietly buried in there: 24-week data just got pushed to Q1 2027, yet another slip. 
 
But here's the part nobody's talking about — those warrants strike at $3.10. We're sitting at $1.58. That cash tap is basically shut off right now 
 
Bad data = No cash, ugly raise (new offering) 
Good data = stock pops near $3, warrants get forced/exercised, instant dilution right as it looks good. 
 
There's no clean outcome here either way.  
Same movie - different scene 🐻

Feed

News

Sentiment

Fundamentals

Info

MTVA MetaVia Inc.

Fundamentals

Latest MTVA News